GestVision

GestVision, Inc. operates as a biotechnology company focused on developing diagnostic tests to improve pregnancy outcomes, specifically targeting preeclampsia. Founded in 2014 by Wendy Davis, the company is headquartered in Groton, Connecticut, and aims to provide healthcare providers with tools for making more confident and timely clinical decisions in women's health.

The company's core technology stems from research initially developed at Yale University, where the concept of using a urine test to detect protein biomarkers for preeclampsia was conceived. Founder and CEO Wendy Davis leveraged her extensive background in biotechnology and an MBA from Yale University to launch GestVision. While attending the Yale School of Management's Executive MBA program, she connected with the research, developed a business plan, and incorporated the company in January 2014. Her previous experience includes roles at HistoRx (acquired by Novartis), Curagen Corporation, and the University of South Florida Moffitt Cancer Center, providing her with a foundation in moving early-stage inventions through commercialization and regulatory approval.

GestVision is developing the GestAssured® test, a rapid, point-of-care urine diagnostic designed to detect misfolded proteins associated with preeclampsia. This condition, a leading cause of maternal mortality and premature births, is notoriously difficult to diagnose, often relying on symptoms like high blood pressure and protein in the urine, which can be indicative of other issues. The GestAssured® test aims to offer a clearer, faster diagnostic method to help doctors rule out preeclampsia or determine which patients require immediate care, potentially avoiding unnecessary preterm deliveries while ensuring the safety of both mother and child. The business serves healthcare providers, particularly those in obstetrics and gynecology, by offering a tool to manage at-risk pregnancies more effectively. The company has pursued a strategy of securing patents, conducting clinical studies, and raising capital to bring its product to market. GestVision has successfully raised $17.2 million over several funding rounds, with notable investors including CooperSurgical and the YEI Innovation Fund.

Keywords: preeclampsia diagnostic, maternal health, point-of-care testing, femtech, biotechnology, women's health, pregnancy complications, urine test, GestAssured, Wendy Davis, diagnostic equipment, medical diagnostics, Yale University spin-off, safer pregnancies, high-risk pregnancy, maternal mortality, fetal health, clinical studies, healthcare innovation, life sciences